Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7th, 2025
Amphastar Pharmaceuticals (NASDAQ:AMPH) has scheduled its second quarter 2025 earnings release and conference call for August 7, 2025. The financial results will be released after market close, followed by a conference call at 2:00 p.m. Pacific Time.
Amphastar is a bio-pharmaceutical company specializing in developing, manufacturing, and marketing technically challenging generic and proprietary injectable, inhalation, and intranasal products. The company also produces insulin API products, with most of its finished products being used in hospital or urgent care clinical settings.
Amphastar Pharmaceuticals (NASDAQ:AMPH) ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 e la conference call per il 7 agosto 2025. I risultati saranno resi noti dopo la chiusura del mercato, seguiti da una conference call alle 14:00 ora del Pacifico.
Amphastar è un'azienda biofarmaceutica specializzata nello sviluppo, produzione e commercializzazione di prodotti iniettabili, per inalazione e intranasali, sia generici che proprietari, caratterizzati da elevata complessità tecnica. L'azienda produce inoltre principi attivi per insulina, con la maggior parte dei suoi prodotti finiti destinati all'uso in ambienti ospedalieri o di pronto soccorso.
Amphastar Pharmaceuticals (NASDAQ:AMPH) ha programado la publicación de sus resultados del segundo trimestre de 2025 y una conferencia telefónica para el 7 de agosto de 2025. Los resultados financieros se darán a conocer después del cierre del mercado, seguidos por una llamada a las 2:00 p.m. hora del Pacífico.
Amphastar es una empresa biofarmacéutica especializada en el desarrollo, fabricación y comercialización de productos inyectables, para inhalación e intranasales, tanto genéricos como propietarios, que presentan desafíos técnicos. La compañía también produce ingredientes activos de insulina, y la mayoría de sus productos terminados se utilizan en entornos clínicos hospitalarios o de atención urgente.
Amphastar Pharmaceuticals (NASDAQ:AMPH)는 2025년 2분기 실적 발표 및 컨퍼런스 콜을 2025년 8월 7일로 예정했습니다. 재무 결과는 시장 마감 후 발표되며, 이어서 태평양 표준시 오후 2시에 컨퍼런스 콜이 진행됩니다.
Amphastar는 기술적으로 까다로운 제네릭 및 독자적인 주사제, 흡입제, 비강 내 제품을 개발, 제조 및 판매하는 바이오 제약 회사입니다. 또한 인슐린 원료 의약품(API)을 생산하며, 완제품의 대부분은 병원이나 응급 진료 환경에서 사용됩니다.
Amphastar Pharmaceuticals (NASDAQ:AMPH) a programmé la publication de ses résultats du deuxième trimestre 2025 et une conférence téléphonique pour le 7 août 2025. Les résultats financiers seront publiés après la clôture du marché, suivis d'une conférence téléphonique à 14h00, heure du Pacifique.
Amphastar est une entreprise biopharmaceutique spécialisée dans le développement, la fabrication et la commercialisation de produits injectables, inhalés et intranasaux génériques et propriétaires techniquement complexes. La société produit également des principes actifs d’insuline, la majorité de ses produits finis étant utilisés dans des environnements cliniques hospitaliers ou de soins d’urgence.
Amphastar Pharmaceuticals (NASDAQ:AMPH) hat die Veröffentlichung der Ergebnisse für das zweite Quartal 2025 und eine Telefonkonferenz für den 7. August 2025 geplant. Die Finanzergebnisse werden nach Börsenschluss veröffentlicht, gefolgt von einer Telefonkonferenz um 14:00 Uhr Pazifischer Zeit.
Amphastar ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung, Herstellung und Vermarktung technisch anspruchsvoller generischer und proprietärer injizierbarer, inhalativer und intranasaler Produkte spezialisiert hat. Das Unternehmen produziert außerdem Insulin-Wirkstoffe (API), wobei die meisten Fertigprodukte in klinischen Umgebungen wie Krankenhäusern oder Notfallzentren eingesetzt werden.
- None.
- None.
RANCHO CUCAMONGA, CA / ACCESS Newswire / July 29, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2025 ended June 30, 2025, after the market closes on Thursday, August 7, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.
The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call.
Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.
Forward Looking Statements
All statements in this press release referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding expansion of our headquarters, including quadrupling our production capacity and manufacturing capabilities, the resilience of our supply chain, our ability to expand our automation capabilities and integrate advanced technologies, our ability to create new jobs in the future, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, in our Quarterly Report on Form 10-Q for the quarter ending March 31, 2025, filed with the SEC on May 8, 2025, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact:
Bill Peters
Chief Financial Officer
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Amphastar (NASDAQ:AMPH) release its Q2 2025 earnings?
How can investors access Amphastar's Q2 2025 earnings conference call?
What time is Amphastar's Q2 2025 earnings call?
What are Amphastar Pharmaceuticals' main product offerings?
Where can investors find the replay of Amphastar's Q2 2025 earnings call?
